New drug combo tested for tough cancers
NCT ID NCT05514444
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 31 times
Summary
This early-phase study tested a new drug called MK-4464, given alone or with another drug (pembrolizumab), in 64 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check safety, how the drug moves through the body, and to find the right dose. This is a first step to see if the approach is worth studying further.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Amsterdam UMC, locatie VUmc ( Site 0400)
Amsterdam, North Holland, 1081HV, Netherlands
-
Hadassah Medical Center-Oncology ( Site 0302)
Jerusalem, 9112001, Israel
-
Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0401)
Amsterdam, North Holland, 1066CX, Netherlands
-
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0201)
Toronto, Ontario, M5G 2M9, Canada
-
Rambam Health Care Campus-Oncology Division ( Site 0300)
Haifa, 3109601, Israel
-
The University of Louisville, James Graham Brown Cancer Center ( Site 0100)
Louisville, Kentucky, 40245, United States
Conditions
Explore the condition pages connected to this study.